Myelodysplastic syndromes (MDS) and anemia: What to know

What are myelodysplastic syndromes?

Bone marrow is the spongy tissue inside certain bones that acts as the body’s blood-cell factory. It produces stem cells that normally mature into three major types of blood cells:

• Red blood cells, which carry oxygen through hemoglobin.
• White blood cells, which help defend the body against infection.
• Platelets, which help control bleeding.

In MDS, acquired genetic changes affect blood-forming stem cells. Many developing cells become misshapen, function poorly, or die before leaving the marrow. The factory may look busy, but too few usable products reach the shipping departmentthat is, the bloodstream.

The resulting shortage of one or more blood-cell types is called cytopenia. A shortage of red blood cells causes anemia. Low neutrophils can increase infection risk, while low platelets may lead to bruising, nosebleeds, pinpoint spots under the skin, or prolonged bleeding.

MDS is considered a myeloid cancer rather than simply “preleukemia.” Some cases remain relatively stable for years, while others progress more quickly or develop into acute myeloid leukemia. The risk varies substantially according to blast percentage, blood counts, chromosome findings, gene mutations, and response to treatment.

Why does MDS cause anemia?

Red blood cells contain hemoglobin, the protein responsible for delivering oxygen to tissues. In MDS, abnormal marrow cells often cannot complete the complicated process of producing mature red blood cells. Many die inside the marrow, and those that reach circulation may not survive or function normally.

This process is known as ineffective erythropoiesis. It explains why a person can have active or even crowded bone marrow but still have a low hemoglobin level. The kitchen is bustling, yet dinner never arrives.

What MDS-related anemia may look like on laboratory tests

MDS anemia is commonly normocytic or macrocytic, meaning the red blood cells may be normal-sized or larger than usual. A complete blood count may show reduced hemoglobin and hematocrit, while a blood smear may reveal cells with unusual sizes or shapes. Reticulocytesyoung red blood cells released into circulationmay be inappropriately low because the marrow is not mounting an effective response.

Some MDS subtypes involve ring sideroblasts, which are immature red cells containing abnormal rings of iron around their nuclei in the bone marrow. This does not mean the person simply needs more iron. In fact, taking iron without evidence of deficiency may be unhelpful and, in transfusion-dependent patients, potentially contribute to excess iron.

Symptoms of anemia in people with MDS

Mild anemia may cause no obvious symptoms and may first appear during a routine blood test. When hemoglobin falls furtheror falls rapidlysymptoms can include:

• Persistent tiredness or reduced stamina
• Weakness, especially during physical activity
• Shortness of breath with exertion
• Dizziness or lightheadedness
• Headaches or difficulty concentrating
• Pale skin, lips, or nail beds
• A fast heartbeat or noticeable palpitations
• Feeling unusually cold
• Chest discomfort in people with heart disease

The hemoglobin number is important, but it is not the entire story. One person may function reasonably well at a level that leaves another unable to walk across a room comfortably. Age, heart and lung health, the speed of the decline, and the body’s ability to adapt all influence symptoms.

When symptoms need urgent attention

Seek immediate medical care for severe trouble breathing, chest pain, fainting, confusion, a very rapid heartbeat, or uncontrolled bleeding. People with low neutrophils should follow their treatment team’s instructions about fever; a temperature of 100.4°F (38°C) or higher commonly requires prompt medical evaluation.

Who is more likely to develop MDS?

MDS occurs most often in older adults, particularly people over age 60, although it can occur earlier. In many cases, no single cause can be identified. Known risk factors include previous chemotherapy or radiation therapy and substantial exposure to certain chemicals, including benzene.

Most MDS is not directly inherited. However, uncommon inherited bone marrow failure or cancer-predisposition syndromes can raise the risk, especially when MDS develops at a younger age or appears alongside a notable family history. In those situations, genetic counseling may be appropriate.

How doctors diagnose MDS-related anemia

Anemia alone does not establish an MDS diagnosis. Iron deficiency, vitamin B12 or folate deficiency, kidney disease, thyroid disorders, inflammation, bleeding, medication effects, alcohol use, hemolysis, and copper deficiency can produce overlapping findings. Doctors therefore investigate both the low blood count and its possible alternatives.

Blood tests

The evaluation usually begins with a complete blood count with differential. Repeated tests help determine whether the abnormality is persistent and whether white cells or platelets are also affected. A reticulocyte count and peripheral blood smear provide clues about marrow production and cell appearance.

Additional testing may include iron studies, ferritin, vitamin B12, folate, kidney and liver tests, thyroid testing, and markers of red-cell destruction. The exact list depends on the person’s symptoms, medical history, medications, diet, and prior laboratory results.

Bone marrow examination

If persistent unexplained cytopenias raise concern for MDS, a hematologist may perform a bone marrow aspiration and biopsy, usually from the back of the hip. The aspiration removes liquid marrow, while the biopsy collects a small core of tissue. Local anesthetic reduces pain, although pressure and brief discomfort are common.

Specialists examine the samples for dysplasia, cell density, iron patterns, and the percentage of immature cells called blasts. Cytogenetic testing looks for chromosome changes such as deletion of part of chromosome 5. Molecular testing can identify acquired gene mutations that help refine the diagnosis, estimate risk, or guide treatment.

Risk classification shapes the treatment plan

MDS does not have a conventional stage such as stage 1 or stage 4. Doctors instead use prognostic systems, including the Revised International Prognostic Scoring System and increasingly molecular models such as the IPSS-M.

These tools consider factors such as hemoglobin, platelet and neutrophil counts, bone marrow blast percentage, chromosome abnormalities, and gene mutations. The resulting risk category helps clinicians estimate how likely the disease is to progress and whether treatment should focus mainly on relieving cytopenias or more aggressively controlling the abnormal marrow clone.

A risk score is a planning tool, not a crystal ball. Age, overall health, personal goals, transfusion needs, treatment tolerance, and changes over time also matter.

How is anemia from MDS treated?

Treatment is individualized. A person with mild, stable anemia and few symptoms may initially need active monitoring rather than immediate medication. Someone experiencing worsening fatigue or regular transfusion needs may benefit from supportive care, anemia-directed medicine, disease-modifying treatment, or a combination.

Red blood cell transfusions

A transfusion can raise hemoglobin relatively quickly and relieve symptoms such as breathlessness and severe fatigue. There is no universal hemoglobin threshold that applies to every patient; symptoms, cardiovascular health, bleeding, laboratory trends, and treatment goals influence the decision.

Repeated transfusions can eventually cause iron overload because the body has no efficient way to remove all the additional iron. Doctors may monitor ferritin and, when appropriate, organ iron levels. Iron-chelation medication may be considered for selected people expected to receive long-term transfusion support.

Erythropoiesis-stimulating agents

Erythropoiesis-stimulating agents, or ESAs, encourage the marrow to produce red blood cells. Epoetin alfa and darbepoetin alfa may help some people with lower-risk MDS, particularly when their natural serum erythropoietin level and transfusion burden are relatively low.

Responses are not guaranteed and may diminish over time. Clinicians monitor hemoglobin carefully because these medications also carry risks, including blood clots and excessive rises in hemoglobin.

Luspatercept

Luspatercept is an erythroid maturation agent that helps developing red blood cells mature more effectively. It is approved for defined groups of adults with lower-risk MDS-related anemia who may need regular transfusions. Eligibility depends on previous treatment, risk category, transfusion needs, and disease characteristics.

Lenalidomide

Lenalidomide can be particularly effective for lower-risk MDS with a deletion involving chromosome 5q. It may reduce or eliminate transfusion requirements in some patients, although it can initially lower white-cell and platelet counts and therefore requires close monitoring.

Imetelstat

Imetelstat is approved for certain adults with low- to intermediate-1-risk MDS and transfusion-dependent anemia who have not responded to, have lost response to, or are ineligible for ESAs. Because it can cause significant reductions in neutrophils and platelets, careful blood-count monitoring is essential.

Disease-modifying therapy

Azacitidine and decitabine are hypomethylating agents that can improve blood counts, reduce transfusion needs, and delay disease progression in some patients. They are commonly considered for higher-risk MDS and selected lower-risk cases that have not responded to anemia-focused treatment.

These drugs usually require multiple treatment cycles before their effectiveness can be judged. Counts may temporarily worsen early in therapy, so patients need monitoring and sometimes transfusion or infection support.

Stem cell transplantation

An allogeneic stem cell transplant replaces abnormal blood-forming cells with healthy donor cells. It is currently the only treatment with established curative potential, but it also carries substantial risks, including serious infections, graft-versus-host disease, organ complications, and treatment-related death.

Eligibility depends on disease risk, age, fitness, other medical conditions, donor availability, and personal preferences. For suitable candidates, consultation with a transplant specialist is often valuable before the disease becomes more advanced.

Everyday strategies for living with MDS and anemia

Good nutrition supports general health, but food alone cannot repair abnormal bone marrow. Iron, folate, or vitamin B12 supplements should be taken only when testing shows a deficiency or a clinician recommends them.

Practical strategies may include pacing demanding activities, resting before exhaustion becomes overwhelming, performing gentle exercise as tolerated, staying hydrated, and asking for help with physically demanding tasks. People with low platelets or neutrophils may need additional precautions tailored to their counts.

Keeping copies of laboratory results and recording transfusion dates, symptoms, and medication side effects can make appointments more productive. Useful questions include:

• What is my MDS subtype and risk category?
• Is anemia the main problem, or are other blood-cell lines affected?
• Were reversible causes of anemia excluded?
• What result would trigger a change in treatment?
• Could I benefit from an ESA, luspatercept, lenalidomide, or imetelstat?
• Should I discuss transplantation or a clinical trial?

Experiences with MDS-related anemia: What daily life can feel like

The experience of MDS anemia often begins quietly. A person may notice that grocery shopping suddenly feels like cardio training or that climbing one flight of stairs requires a strategic pause halfway up. Because fatigue is common and invisible, family members may underestimate its impact. The person does not merely feel sleepy; reduced oxygen delivery can make muscles heavy, thinking slower, and ordinary activities disproportionately demanding.

Consider a composite example of a retired teacher whose routine blood work shows macrocytic anemia. Vitamin levels are normal, and the count remains low over several months. After a bone marrow biopsy and genetic testing, lower-risk MDS is diagnosed. At first, monitoring is appropriate because symptoms are mild. The teacher starts planning errands for the morning, rests before social events, and tracks hemoglobin results. This is not “doing nothing.” Active monitoring is a deliberate strategy that avoids treatment burdens while watching carefully for meaningful change.

Another composite experience involves a person who gradually becomes transfusion-dependent. Before each transfusion, concentration fades and walking from the parking lot feels like hauling luggage uphill. Afterward, breathing and energy improve, but the benefit lasts only a few weeks. The repeating cycle can affect travel, employment, caregiving, and emotional well-being. Scheduling life around blood-bank appointments is not anyone’s dream hobby.

For this person, treatment is about more than reaching an attractive laboratory number. A meaningful response might mean needing fewer transfusions, cooking dinner without stopping twice, or attending a grandchild’s game without worrying about the distance from the parking lot. Discussing these practical goals helps the medical team evaluate whether therapy is improving quality of life.

A third composite scenario involves starting a medication such as an ESA, luspatercept, lenalidomide, imetelstat, or a hypomethylating agent. The waiting period can be frustrating because improvement is not always immediate. Laboratory appointments multiply, and early count changes may create anxiety. A symptom diary can provide useful context: Is walking easier? Are naps shorter? Are transfusions farther apart? Numbers matter, but so does the person living between the numbers.

Emotionally, MDS can produce uncertainty because its course differs dramatically among individuals. Some people fear leukemia every time a count changes, while others struggle to explain why they look well but cannot sustain their former pace. Counseling, support groups, patient organizations, and honest conversations with loved ones can reduce isolation.

Caregivers have experiences of their own. They may coordinate appointments, monitor fevers, provide transportation, and quietly worry about the future. Sharing responsibilities and asking the healthcare team for clear written instructions can prevent caregiving from becoming a one-person endurance event.

The central lesson is that MDS-related anemia should be managed according to both disease biology and lived experience. Treatment success may mean longer survival, slower progression, fewer transfusions, better stamina, or simply more good hours in the day. Those goals deserve regular discussion because they may change as the disease and the person’s priorities evolve.

Conclusion

Myelodysplastic syndromes disrupt normal blood-cell development, and anemia is often their most noticeable consequence. Persistent fatigue, shortness of breath, dizziness, or unexplained macrocytic anemia deserves a thoughtful evaluation rather than an automatic bottle of iron.

Diagnosis usually combines repeated blood tests with a bone marrow examination, chromosome analysis, and molecular testing. Treatment ranges from monitoring and transfusions to anemia-directed medicines, disease-modifying therapy, clinical trials, and stem cell transplantation. The right approach depends on the MDS subtype, risk category, symptoms, transfusion burden, health status, and personal goals.